The significant reduction in the price target from $13 to $7.5 suggests that the analyst sees potential downside risks or challenges for Herbalife. Maintaining a Neutral rating indicates no strong buy or sell recommendation, but the lowered target could lead to negative sentiment and potential short-term price decline.